Big Pharma's Internationalization of R&D to China

  title={Big Pharma's Internationalization of R&D to China},
  author={Seamus Grimes and M. Miozzo},
  journal={European Planning Studies},
  pages={1873 - 1894}
  • Seamus Grimes, M. Miozzo
  • Published 2015
  • Economics
  • European Planning Studies
  • Abstract China's increasing integration into the global pharmaceutical value chain is occurring at a time when big pharma's traditional R&D model has entered a period of crisis, and when China faces significant challenges in providing healthcare for its huge and rapidly ageing population. Despite China's ambitions of promoting its own pharmaceutical sector, it is likely to continue to depend for some time on significant contributions from foreign companies. While this situation provides… CONTINUE READING
    Exploring the Asian innovation networks (AINs) characteristics
    • 2


    Publications referenced by this paper.
    Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline
    • 88
    • PDF
    Lessons from 60 years of pharmaceutical innovation
    • 909
    • PDF
    Evolving R&D for emerging markets
    • Medicine
    • 2010
    • 15
    The Emergence of China and India as New Competitors in MNCs' Innovation Networks
    • 96
    Building effective R&D capabilities abroad.
    • 691
    The R&D Activities of Foreign Firms in the United States
    • 373
    State-sponsored Research and Development: A Case Study of China's Biotechnology
    • 39
    • PDF
    A Setback For Chinese Drug R&D
    • 1
    Managing the internationalization of R&D activities
    • 143